fashion -WSS

fashion

author：explore 2025-09-28 01:16:31 - browse：47996

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed. Joe Raedle/Getty Images

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed, per reports from Bloomberg.

Experts largely hailed the rumored sale as a good buy, citing the management of chronic conditions in the Medicare Advantage population through primary care, ChenMed’s specialty, as an area with huge innovation and cost savings over the last 10 years.

“If you’re going to purchase primary care in the senior space, there’s no one better than ChenMed. The only other one that might be better or equivalent would be Oak Street, but they were just purchased,” said Jon Kaplan, a senior partner at BCG. “In the world of great primary care practices to buy, in my top two are Oak Street and ChenMed, and one of them’s available, one’s not.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Microbiome research is starting to find links to chronic diseases

WSS

Neuroscience startup Neumora files for IPO

It's been 20 years since Dolly the sheep. Where's my clone?

It's been 20 years since Dolly the sheep. Where's my clone?

Intarcia’s device

Why more medical students aren't specializing in primary care

Readout LOUD podcast: possible new ALS drug, artificial wombs

hotspot

fashion

entertainment

Alkermes shareholders re

Neuroscience startup Neumora files for IPO

Walensky prepares to leave CDC — and Congress — behind

Diversity in medical illustrations gets boost from Chidiebere Ibe

Peter Hotez and the public health issue of online harassment

How Long Island became the ‘eugenics capital of the world’

Alkermes shareholders re

CommonSpirit Health keeps growing, even as it loses money

Hollywood unions extend contract negotiations for actors

Thermo Fisher plant for manufacturing gene therapies to expand

focus

STAT Virtual Event: Putting AI to the Test

Second xenotransplant done with gene

Intarcia’s device

How to make AI work for medicine

Biotech stock slump in 2023: awaiting the turnaround

Changes to biosimilar regulatory framework must prioritize patients

hotspot

hotspot

entertainment

focus